Spectrum Pharmaceuticals Successfully Defends Against Shareholder Class Action Suit

Represented Spectrum Pharmaceuticals (NAS: SPPI) in connection with parallel derivative and securities class action litigation as well as related regulatory inquiries.The plaintiffs alleged that defendants disseminated false information about Spectrum's oncology drug, Fusilev.